3A4, a new potential target for B and myeloid lineage leukemias

References

• Akifusa S, Heywood W, Nair SP, Stenbeck G, Henderson B. (2005). Mechanism of internalization of the cytolethal distending toxin of Actinobacillus actinomycetemcomitans. Microbiology (Reading, Engl), 151, 1395–1402.
   PubMed Web of Science ®Google Scholar
• Beckman I, Shepherd K, Dimopoulos K, Ahern M, Firgaira F, Bradley J. (1994). Differential expression and regulation of cytokine mRNAs in normal human CD45R T cell subsets. Cytokine, 6, 116–123.
   PubMed Web of Science ®Google Scholar
• Brod SA, Rudd CE, Purvee M, Hafler DA. (1989). Lymphokine regulation of CD45R expression on human T cell clones. J Exp Med, 170, 2147–2152.
   PubMed Web of Science ®Google Scholar
• Bunjes D. (2002). 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma, 43, 2125–2131.
   PubMed Web of Science ®Google Scholar
• Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN. (2001). Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood, 98, 565–572.
   PubMed Web of Science ®Google Scholar
• Chao TC, Walter RJ, Greager JA. (1997). Binding and internalization of anti-sarcoma IgG and IgM antibodies. J Surg Res, 70, 27–33.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. (2005). Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol, 23, 4110–4116.
   PubMed Web of Science ®Google Scholar
• Ferrari M, Fornasiero MC, Isetta AM. (1990). MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods, 131, 165–172.
   PubMed Web of Science ®Google Scholar
• Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B, Berrie E, Bird P, Hale G, Blumstein NM, Waldmann H, Bunjes D, Reske SN. (2006). Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med, 47, 1335–1341.
   PubMed Web of Science ®Google Scholar
• Hermiston ML, Xu Z, Weiss A. (2003). CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol, 21, 107–137.
   PubMed Web of Science ®Google Scholar
• Holmes N. (2006). CD45: all is not yet crystal clear. Immunology, 117, 145–155.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–497.
   PubMed Web of Science ®Google Scholar
• Kulkarni PN, Blair AH, Ghose TI. (1981). Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res, 41, 2700–2706.
   PubMed Web of Science ®Google Scholar
• Li JL, Cai YC, Liu XH, Xian LJ. (2006). Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs, 17, 307–314.
   PubMed Web of Science ®Google Scholar
• Li S, Tang Y. (2010). Accurate determination of internalization for target binding antibody using papain digestion and flow cytometry. Hybridoma (Larchmt), 29, 133–139.
   PubMed Web of Science ®Google Scholar
• Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD. (2007). Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem Toxicol, 45, 1678–1687.
   PubMed Web of Science ®Google Scholar
• Marshall JD, Eveland WC, Smith CW. (1958). Superiority of fluorescein isothiocyanate (Riggs) for fluorescent-antibody technique with a modification of its application. Proc Soc Exp Biol Med, 98, 898–900.
   PubMed Web of Science ®Google Scholar
• Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW. (1995). Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood, 85, 1122–1131.
   PubMed Web of Science ®Google Scholar
• Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, Matthews DC, Deeg HJ, Gopal AK, Martin PJ, Storb RF, Press OW, Appelbaum FR. (2009). Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 114, 5444–5453.
   PubMed Web of Science ®Google Scholar
• Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW. (2003). Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood, 101, 2340–2348.
   PubMed Web of Science ®Google Scholar
• Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, Mao YQ, Kan B, Lei S, Wang GS, Jiang Y, Wang QR, Luo F, Zou LQ, Liu JY. (2002). Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol, 128, 223–230.
   PubMed Web of Science ®Google Scholar
• Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. (2005). CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant, 35, 1127–1132.
   PubMed Web of Science ®Google Scholar
• Sorensen RU, Kallick MD. (1988). Clinical uses of intravenous immune globulin: immunoglobulin replacement therapy and treatment of autoimmune cytopenias. J Clin Apher, 4, 97–103.
   PubMedGoogle Scholar
• Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother, 5, 213–226.
   PubMedGoogle Scholar
• The TH, Feltkamp TE. (1970). Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology, 18, 875–881.
   PubMed Web of Science ®Google Scholar
• Vernier J, Jarrossay D, Agthoven AV. (2002). Non-lineage antigen blind panel: biochemical analysis report. In: Leucocyte Typing VII, Mason D et al (Eds). Oxford University Press, New York, pp. 453–461.
   Google Scholar
• Xu XJ, Tang YM, Song H, Yang SL, Shi SW, Wei J. (2010). Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children’s hospital in China. Leuk Lymphoma, 51, 2262–2269.
   PubMed Web of Science ®Google Scholar
• Yao TJ, Scheinberg DA. (2000). Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res, 6, 372–380.
   PubMed Web of Science ®Google Scholar